With the unveiling of three new preclinical programs, Alkermes plc is fulfilling ambitions first stated in 2011 to evolve from partnering drug delivery technology to discovering and developing its own in-house products, including its first biologic.

The programs are focused on developing modified versions of marketed drugs. Alkermes plans to submit INDs and start Phase I trials of all three NMEs next year, Chairman and CEO Richard Pops said at an R&D day last month, where the programs were first disclosed.